Table 1.
Patient Demographics
| Patient No. | Diagnosis | Age (years) | Prior Chemotherapy Regimens (n) | Previous Radiation Tx | Disease at Trial Entry | Time from Dx to Tx (months) | Seprehvir Dose (iu) |
|---|---|---|---|---|---|---|---|
| HSV01 | pleomorphic rhabdomyosarcoma | 30 | VCR/Irino/Doxo/CTX/Etop, VCR/Dactino/CTX, Ifos/Carbo/Etop, liposomal Doxo/temsirolimus (4) | 45 Gy retroperitoneum | multiple pleural and diaphragmatic nodules, paraspinal mass, lung mets | 19 | 2 × 106 |
| HSV02 | cholangiocarcinoma | 18 | cisplatin/gemcitabine, bevacizumab/5-FU/leucovorin/oxaliplatin, cisplatin/gemcitabine (3) | none | intrahepatic biliary mass, multiple liver mets, mediastinal node | 18 | 2 × 106 |
| HSV03 | pancreatic neuroendocrine tumor | 28 | Temodar/Xeloda, everolimus, Doxo (3) | none | mass in bed of pancreatic head, three liver lesions, mass near SMA, mesenteric nodes | 27 | 2 × 106 |
| HSV04 | Ewing sarcoma | 25 | VCR/Doxo/CTX/Ifos/Etop, Irino/Temodar, VCR/CTX/Topo/bevacizumab (3) | 56 Gy right knee, 18 Gy lung | right tibial mass with two distal lesions and multiple pulmonary nodules | 50 | 2 × 106 |
| HSV05 | osteosarcoma | 17 | MTX/Doxo/Cisplat, high-dose ifosfamide, liposomal Doxo, gemcitabine/docetaxel, gemcitabine, and nab-paclitaxel (5) | none | multiple pleural, lung, and diaphragmatic nodules | 26 | 2 × 106 |
| HSV06 | rhabdomyosarcoma | 11 | VCR/Irino/Doxo/Dactino/CTX/Etop, vinorelbine/CTX/temsirolimus (2) | 37.5 Gy humeri; 41.4 Gy cervical, thoracic, and sacral spine; 37.5 Gy foot | pelvic mass, abdominal and inguinal nodes, thigh mass, bilateral lung and hilar nodules, liver nodules | 26 | 1.6 × 106 |
| HSV07 | osteosarcoma | 19 | Doxo/cisplatin/Zometa/HD-MTX/Ifos/Etop, high-dose ifos, gemcitabine/Taxotere, sorafenib, liposomal doxo (5) | none | right upper lung mass with satellite nodules and right subcarinal node | 53 | 1 × 107 |
| HSV08 | neuroblastoma | 16 | CTX/Doxo/VCR/Cisplat/Etop; Carbo/Etop/Mel, retinoic acid, Irino/Temodar, CTX/Topo, anti-GD2 immunotherapy, oral etoposide, AZD1775/oral Irino (8) | 21.6 Gy abdomen and skull, XRT to thigh (dose unknown) | entire right hip bone, right hip mass, left femoral head, right liver lobe mets, and L4/S1 vertebral bodies | 132 | 1 × 107 |
| HSV09 | chondrosarcoma | 29 | MTX/Doxo/Cisplat, Doxo, Ifos/Etop, pazopanib, Ifos/Etop (5) | proton XRT to thigh (dose unknown) | large pelvic/sacral mass into the sacral canal, paraspinal, and gluteal muscles | 54 | 1 × 107 |
5-FU, fluorouracil; Carbo, carboplatin; Cisplat, cisplatin; CTX, cyclophosphamide; Dactino, dactinomycin; Doxo, doxorubicin; Dx, diagnosis; Etop, etoposide; HD-MTX, high-dose methotrexate; Ifos, ifosfamide; Irino, irinotecan; Mel, melphalan; SMA, superior mesenteric artery; Tx, therapy; VCR, vincristine; XRT, radiation therapy.